Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pulse Biosciences CS
(NQ:
PLSE
)
21.48
-0.05 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pulse Biosciences CS
< Previous
1
2
3
4
5
Next >
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
September 29, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
September 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
September 07, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Clarifies Details of Recent S-3 Filing
August 24, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
August 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
July 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
May 18, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
May 11, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
May 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
May 03, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces $65 Million Private Placement
May 01, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
April 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
March 30, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
March 02, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium
February 02, 2023
From
Pulse Biosciences
Via
Business Wire
Pulse Biosciences Reports Third Quarter 2022 Financial Results
November 10, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
October 27, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
October 06, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
September 26, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
September 20, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Reports Second Quarter 2022 Financial Results
August 10, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
August 04, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
July 27, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
June 09, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Pulse Biosciences, Inc. (NASDAQ:PLSE) Long Term Investor Alert: Investigation of Potential Wrongdoing
June 03, 2022
San Diego, CA -- (SBWIRE) -- 06/03/2022 -- Certain directors of Pulse Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
June 03, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm
May 23, 2022
From
The Schall Law Firm
Via
Business Wire
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
May 19, 2022
From
Pulse Biosciences
Via
Business Wire
Pulse Biosciences Reports First Quarter 2022 Financial Results
May 11, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.